Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy

Cancer

Volumn 106, Issue 4, 2006, Pages 775-782

  Steuber, Thomas ^a   Erbersdobler, Andreas ^a   Graefen, Markus ^a   Haese, Alexander ^a   Huland, Hartwig ^a   Karakiewicz, Pierre I ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Biochemical recurrence; Prostate carcinoma; Radical prostatectomy; Staging; TNM staging classification

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; COMPARATIVE STUDY; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATE CARCINOMA; PROSTATECTOMY;

DISEASE-FREE SURVIVAL; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 32544455982     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21632     Document Type: Article

References (21)

1. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
2. Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA. 1996;276:615-619.
3. D'Amico AV, Whittington R, Malkowicz SB, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol. 1995;154:131-138.
4. Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol. 2001;165:119-125.
5. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499-1507.
6. Beahrs O, Henson D, Hutter R, et al, editors. AJCC cancer staging manual, 4th ed. Philadelphia: Lippincott-Raven, 1992.
7. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766-771.
8. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997;24:395-406.
9. Fleming ID, Cooper JS, Henson DE, et al., editors. AJCC cancer staging manual 5th ed. Philadelphia: Lippincott-Raven, 1998.
10. Greene FL, Page DL, Fleming ID, et al., editors AJCC cancer staging manual, 6th ed. New York: Springer-Verlag, 2002.
11. May F, Hartung R, Breul J. The ability of the American Joint Committee on Cancer staging system to predict progression-free survival after radical prostatectomy. BJU Int. 2001;88:702-707.
12. Yossepowitch O, Engelstein D, Konichezky M, Sella A, Livne PM, Baniel J. Bladder neck involvement at radical prostatectomy: positive margins or advanced T4 disease? Urology. 2000;56:448-452.
13. Conrad S, Graefen M, Pichlmeier U, et al. Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma. J Urol. 2002;167(2 Pt 1):521-525.
14. McNeal JE, Redwine EA, Freiha ES, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;12:897-906.
15. Gleason DF. Histologic grading and clinical staging of prostate carcinoma. In: Tannenbaum M, editor. Urologic pathology: the prostate. Philadelphia: Lea and Feibiger, 1977:171-197.
16. Begg CB, Cramer LD, Venkatraman ES, Rosai J. Comparing tumour staging and grading systems: a case study and a review of the issues, using thymoma as a model. Stat Med. 2000;19:1997-2014.
17. Graefen M, Ohori M, Karakiewicz PI, et al. Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol. 2004;171:200-203.
18. Cagiannos I, Graefen M, Karakiewicz PI, et al. Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement? J Clin Oncol. 2002;20:2025-2030.
19. Noldus J, Graefen M, Haese A, Henke RP, Hammerer P, Huland H. Stage migration in clinically localized prostate cancer. Eur Urol. 2000;38:74-78.
20. Dillioglugil O, Leibman BD, Kattan MW, Seale-Hawkins C, Wheeler TM, Scardino PT. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology. 1997;50:93-99.
21. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000;164:101-105.